当前位置: 首页 >> 检索结果
共有 63007 条符合本次的查询结果, 用时 3.9153625 秒

21. Myocardial Infarction, Precision-Engineered T Regulatory Cells to the Rescue.

作者: Liwu Li.
来源: Circulation. 2026年153卷13期998-1000页

22. Group 1 Pulmonary Hypertension With Elevated Pulmonary Artery Wedge Pressure: Characterizing A Complex Phenotype.

作者: Lindsay M Forbes.;William K Cornwell.
来源: Circulation. 2026年153卷13期963-966页

23. Transient Sprr1a Expression Defines a Population of Border Zone Cardiomyocytes That Survive Ischemic Injury.

作者: Emily H Marshall.;Daniel A Zuppo.;Kimberly N Burgos Villar.;Adwiteeya Misra.;Deanne M Mickelsen.;Ronald A Dirkx.;Eric M Small.
来源: Circulation. 2026年153卷13期1001-1004页

24. Response by Gao et al to Letter Regarding Article, "G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice".

作者: Pan Gao.;Liliang Li.;Yunzeng Zou.
来源: Circulation. 2026年153卷13期e1057页

25. Letter by Meng et al Regarding Article, "An Aberrant Resurgence of Endogenous Retroviruses Prompts Myocarditis and Heart Failure".

作者: Chang Meng.;Yintang Wang.;Guobin Miao.
来源: Circulation. 2026年153卷13期e1058页

26. Letter by Wu et al Regarding Article, "G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice".

作者: Di Wu.;Jing Zhang.;Jian Yang.
来源: Circulation. 2026年153卷13期e1055-e1056页

27. Competing Risks in Cardiovascular Research: A Practical Perspective.

作者: Andrea Bellavia.;Sabina A Murphy.
来源: Circulation. 2026年153卷13期945-947页

28. Response by Xiong and Zhang to Letter Regarding Article, "An Aberrant Resurgence of Endogenous Retroviruses Prompts Myocarditis and Heart Failure".

作者: Junhao Xiong.;Bing Zhang.
来源: Circulation. 2026年153卷13期e1059-e1060页

29. Response by Hundemer and Vaidya to Letter Regarding Article, "Subclinical Primary Aldosteronism and Major Adverse Cardiovascular Events: A Longitudinal Population-Based Cohort Study".

作者: Gregory L Hundemer.;Anand Vaidya.
来源: Circulation. 2026年153卷13期e1053-e1054页

30. Letter by Xu and Sun Regarding Article, "Subclinical Primary Aldosteronism and Major Adverse Cardiovascular Events: A Longitudinal Population-Based Cohort Study".

作者: Jiaqian Xu.;Yinghan Sun.
来源: Circulation. 2026年153卷13期e1052页

31. Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID Trials.

作者: Sreekanth Vemulapalli.;Karla Pena Guerra.;Daniel Wojdyla.;W Schuyler Jones.;Kenneth W Mahaffey.;Robert A Harrington.;Philippe Gabriel Steg.;Gregory G Schwartz.;Manesh R Patel.;Renato D Lopes.;Ricardo Henao.
来源: Circulation. 2026年
Clinical endpoint classification (CEC) is the gold standard for cardiovascular endpoint measurement in clinical trials, but adds time and cost. We developed and validated an artificial intelligence (AI) algorithm (ADAPT-CEC) that adjudicates multiple cardiovascular endpoints and adapts to new definitions.

32. Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study.

作者: Nicholas A Marston.;Brian A Bergmark.;Thomas A Prohaska.;Filipe A Moura.;Andre Zimerman.;Veronica J Alexander.;Yu Mi Kang.;Julia Weinland.;Xinhui Ran.;Sabina A Murphy.;Shuanglu Zhang.;Dan Li.;Maciej Banach.;Erik S G Stroes.;Robert Kiss.;Daniel Gaudet.;Michal Vrablik.;Assen Goudev.;Jeroen J Bax.;Matthew J Budoff.;Borek Foldyna.;Michael T Lu.;Sotirios Tsimikas.;Robert P Giugliano.;Marc S Sabatine.
来源: Circulation. 2026年
Whether lowering triglyceride-rich lipoproteins and remnant cholesterol favorably modifies coronary atherosclerosis is unclear. Olezarsen, an antisense oligonucleotide that targets apolipoprotein C-III, reduces triglycerides by ~60% and remnant cholesterol by ~70%, has a neutral effect on LDL cholesterol (LDL-C), and reduces apolipoprotein B (apoB) by ~15% in moderate hypertriglyceridemia. We investigated the effect of olezarsen on coronary plaque in adults with largely moderate hypertriglyceridemia.

33. A New Dawn for Pre-hospital Heparin in STEMI? Insights from the HEPARIN STEMI Trial.

作者: Diana A Gorog.;Antonio Landi.
来源: Circulation. 2026年

34. Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI: HEPARIN STEMI Randomized Controlled Trial.

作者: Misa Fister.;Marko Noc.;Peter Radsel.;Matjaz Bunc.;Danilo Franco.;Tomaz Goslar.; .
来源: Circulation. 2026年
Primary PCI is the preferred reperfusion strategy in patients with ST-elevation myocardial infarction (STEMI). We investigated benefits and safety of pretreatment with unfractioned heparin (UFH) in STEMI referred to primary PCI.

35. The Role of Atrial Pacing Support in Cardiac Resynchronization Therapy: A Non-Inferiority Randomized Trial.

作者: Mauro Biffi.;Giovanni Rovaris.;Ennio Carmine Luigi Pisanò.;Valeria Calvi.;Antonio Rapacciuolo.;Matteo Santamaria.;Giampiero Maglia.;Gabriele Zanotto.;Emanuele Bertaglia.;Gerardo Nigro.;Andrea Giomi.;Francesca Notarangelo.;Patrizia Pepi.;Giuliano D'Alterio.;Davide Castagno.;Antonio Dello Russo.;Antonino Nicosia.;Massimo Zecchin.;Matteo Bertini.;Antonio Duca.;Daniele Giacopelli.;Alessio Gargaro.;Giovanni Luca Botto.; .
来源: Circulation. 2026年
The role of atrial pacing support is unclear in cardiac resynchronization therapy-defibrillator (CRT-D) patients without sinus node dysfunction.

36. Expecting the Unexpected: Insights and Uncertainties From the ALTERRA Trial 3-Year Results.

作者: Qiao J Han.;Doff B McElhinney.;Ada C Stefanescu Schmidt.
来源: Circ Cardiovasc Interv. 2026年e016575页

37. From Signal to Surveillance: Assessing the Role of MicroRNAs in Cardiac Allograft Rejection.

作者: Lauren K Truby.;Maryjane Farr.
来源: Circ Heart Fail. 2026年e014207页

38. Response by Oikonomou et al to Letter Regarding Article, "Artificial Intelligence-Enabled Echocardiography as a Surrogate for Multimodality Aortic Stenosis Imaging: Post Hoc Analysis of a Clinical Trial".

作者: Evangelos K Oikonomou.;Marc R Dweck.;Rohan Khera.
来源: Circ Cardiovasc Imaging. 2026年e019756页

39. Preventing Complications of Mechanical Circulatory Support Devices: The Clue for Improved Outcomes?

作者: Uwe Zeymer.;Dirk Westermann.;Holger Thiele.
来源: Circ Cardiovasc Interv. 2026年e016174页

40. Sotatercept for Combined Post- and Pre-capillary Pulmonary Hypertension Associated With Heart Failure: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study.

作者: Mardi Gomberg-Maitland.;Ryan J Tedford.;David Langleben.;Stephan Rosenkranz.;Barry Miller.;Aaron D Jones.;Alessia Urbinati.;Ciaran J McMullan.;Alexandra G Cornell.;Jean-Luc Vachiery.
来源: Circulation. 2026年
Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction (CpcPH-HFpEF) involves remodeling in both the heart and pulmonary vasculature. Despite significant mortality, there are no proven therapies.
共有 63007 条符合本次的查询结果, 用时 3.9153625 秒